Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APalutamide and stEReotactic Body Radiation Therapy for Low Burden Metastatic Hormone senSItive Prostate Cancer, a rANdomized Trial - PERSIAN

NCT05717660 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria Careggi as lead sponsor.

NCT NCT05717660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APalutamide and stEReotactic Body Radiation Therapy for Low Burden Metastatic Hormone senSItive Prostate Cancer, a rANdomized Trial - PERSIAN
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Phase
Phase 2
Overall status
Unknown status
Start date
March 11, 2023
Completion date
March 11, 2025
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic hormone sensitive prostate cancer